Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers

European Journal of Pharmaceutical Sciences

Volumn 16, Issue 4-5, 2002, Pages 237-246

  Rege, Bhagwant D ^a   Kao, Joseph P Y ^b   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

Human intestinal peptide transporter (hPepT 1); Monocarboxylic acid transporter (MCT); Nonionic surfactants; P glycoprotein (P gp); Transporters

Indexed keywords

BIOLOGICAL MEMBRANES; CARBOXYLIC ACIDS; CELLS; ENZYME INHIBITION; ENZYMES; LIPIDS; MONOLAYERS; SURFACE ACTIVE AGENTS;

LIPID BILAYERS;

DRUG PRODUCTS;

ALPHA TOCOPHEROL; ALPHA TOCOPHERYL POLYETHLENE GLYCOL 800 SUCCINATE; BENZOIC ACID; CARBOXYLIC ACID; CARRIER PROTEIN; CREMOPHOR; GLUCOSIDE; GLYCOPROTEIN P; GLYCYLSARCOSINE; MEMBRANE PROTEIN; N OCTYL GLUCOSIDE; NONIONIC SURFACTANT; PEPTIDE; POLYSORBATE 80; PROTEIN KINASE C; RHODAMINE; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE FLUIDITY; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE TRANSPORT; CELL STRAIN CACO 2; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; INHIBITION KINETICS; INTESTINE ABSORPTION; LIPID BILAYER; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CADHERINS; CARRIER PROTEINS; CELL MEMBRANE PERMEABILITY; DIPEPTIDES; GLYCEROL; HUMANS; MEMBRANE FLUIDITY; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MONOCARBOXYLIC ACID TRANSPORTERS; P-GLYCOPROTEIN; POLYETHYLENE GLYCOLS; POLYSORBATES; PROTEIN KINASE C; RHODAMINE 123; SURFACE-ACTIVE AGENTS; VITAMIN E;

EID: 0036741452     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(02)00055-6     Document Type: Article

References (37)

1. Badary O.A., Al-Shabanah O.A., Al-Gharably N.M., Elmazar M.M. Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice. Anticancer Drugs. 9:1998;809-815.
2. + co-transport system in the Caco-2 human colon carcinoma cell line. Biochem. J. 299:1994;253-260.
3. Castro A.F., Horton J.K., Vanoye C.G., Altenberg G.A. Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers. Biochem. Pharmacol. 58:1999;1723-1733.
4. Chang T., Benet L.Z., Hebert M.F. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 59:1996;297-303.
5. Chervinsky D.S., Brecher M.L., Baker R.M., Hoelcle M.J., Tebbi C.K. Reversal of C1300 murine neuroblastoma multidrug resistance by cremophor EL, a solvent for cyclosporin A. Cancer Biother. 8:1993;67-75.
6. Davis W.W., Pfeiffer R.R., Quay J.F. Normal and promoted gastrointestinal absorption of water-soluble substances. I. Induced rapidly reversible hyperabsorptive state in the canine fundic stomach pouch. J. Pharm. Sci. 59:1970;960-963.
7. Dudeja P.K., Anderson K.M., Harris J.S., Buckingham L., Coon J.S. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch. Biochem. Biophys. 319:1995;309-315.
8. Germann U.A., Chambers T.C., Ambudkar S.V., Pastan I., Gottesman M.M. Effects of phosphorylation of P-glycoprotein on multidrug resistance. J. Bioenerg. Biomembr. 27:1995;53-61.
9. Hu M., Zheng L., Chen J., Liu L., Zhu Y., Dantzig A.H., Stratford R.E. Jr. Mechanisms of transport of quinapril in Caco-2 cell monolayers: comparison with cephalexin. Pharm. Res. 12:1995;1120-1125.
10. Koga K., Murakami M., Kawashima S. Effects of fatty acid sucrose esters on ceftibuten transport by rat intestinal brush-border membrane vesicles. Biol. Pharm. Bull. 21:1998;747-751.
11. Koga K., Murakami M., Kawashima S. Effects of fatty acid glycerol esters on intestinal absorptive and secretory transport of ceftibuten. Biol. Pharm. Bull. 22:1999;402-406.
12. Koga K., Murakami M., Kawashima S. Modification of ceftibuten transport by changes in lipid fluidity caused by fatty acid glycerol esters. Biol. Pharm. Bull. 22:1999;103-106.
13. Koga K., Ohyashiki T., Murakami M., Kawashima S. Modification of ceftibuten transport by the addition of non-ionic surfactants. Eur. J. Pharm. Biopharm. 49:2000;17-25.
14. Lebo D.B., Gupta P.K. Modulation of membrane cholesterol content in cultured LLC-PK1 cells. Int. J. Pharm. 125:1995;1-5.
15. Lee H.J., Balasubramanian S.V., Murer H., Biber J., Morris M.E. Modulation of sulfate renal transport by alterations in cell membrane fluidity. J. Pharm. Sci. 88:1999;976-980.
16. Lentz K.A., Polli J.W., Wring S.A., Humphreys J.E., Polli J.E. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm. Res. 17:2000;1456-1460.
17. Miller D.W., Batrakova E.V., Kabanov A.V. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm. Res. 16:1999;396-401.
18. Mountfield R.J., Senepin S., Schleimer M., Walter I., Bittner B. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int. J. Pharm. 211:2000;89-92.
19. Nabekura T., Takano M., Kimura M., Yasuhara M., Inui K. Modulation of organic cation transport and lipid fluidity by benzyl alcohol in rat renal brush-border membranes. Pharm. Res. 13:1996;1069-1072.
20. Nerurkar M.M., Burton P.S., Borchardt R.T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13:1996;528-534.
21. Nerurkar M.M., Ho N.F., Burton P.S., Vidmar T.J., Borchardt R.T. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci. 86:1997;813-821.
22. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., Woolley J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16:1999;1206-1212.
23. Rege B.D., Yu L.X., Hussain A.S., Polli J.E. Effect of common excipients on Caco-2 transport of low permeability drugs. J. Pharm. Sci. 90:2001;1776-1786.
24. Saeki T., Shimabuku A.M., Ueda K., Komano T. Specific drug binding by purified lipid-reconstituted P-glycoprotein: dependence on the lipid composition. Biochim. Biophys. Acta. 1107:1992;105-110.
25. Sinicrope F.A., Dudeja P.K., Bissonnette B.M., Safa A.R., Brasitus T.A. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J. Biol. Chem. 267:1992;24995-25002.
26. Sokol R.J., Johnson K.E., Karrer F.M., Narkewicz M.R., Smith D., Kam I. Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet. 338:1991;212-214.
27. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 94:1997;2031-2035.
28. Thwaites D.T., Brown C.D., Hirst B.H., Simmons N.L. Transepithelial glycylsarcosine transport in intestinal Caco-2 cells mediated by expression of H(+)-coupled carriers at both apical and basal membranes. J. Biol. Chem. 268:1993;7640-7642.
29. Thwaites D.T., Brown C.D., Hirst B.H., Simmons N.L. H(+)-coupled dipeptide (glycylsarcosine) transport across apical and basal borders of human intestinal Caco-2 cell monolayers display distinctive characteristics. Biochim. Biophys. Acta. 1151:1993;237-245.
30. Troutman M.D., Thakker D.R. P-glycoprotein (P-gp) is not responsible for the inability of rhodamine 123 to enter Caco-2 cells across apical membrane during absorptive transport. AAPSPharmSci. 3:2001;online.
31. Tsuji A., Takanaga H., Tamai I., Terasaki T. Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism. Pharm. Res. 11:1994;30-37.
32. van Heeswijk R.P., Veldkamp A., Mulder J.W., Meenhorst P.L., Lange J.M., Beijnen J.H., Hoetelmans R.M. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir. Ther. 6:2001;201-229.
33. Woodcock D.M., Linsenmeyer M.E., Chojnowski G., Kriegler A.B., Nink V., Webster L.K., Sawyer W.H. Reversal of multidrug resistance by surfactants. Br. J. Cancer. 66:1992;62-68.
34. Wu X., Whitfield L.R., Stewart B.H. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm. Res. 17:2000;209-215.
35. Yu L., Bridgers A., Polli J., Vickers A., Long S., Roy A., Winnike R., Coffin M. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 16:1999;1812-1817.
36. Yumoto R., Murakami T., Nakamoto Y., Hasegawa R., Nagai J., Takano M. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Pharmacol. Exp. Ther. 289:1999;149-155.
37. Zhao F.K., Chuang L.F., Israel M., Chuang R.Y. Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159:1989;1359-1367.